Canaccord Genuity Maintains Buy on Health Catalyst, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a 'Buy' rating on Health Catalyst (NASDAQ:HCAT) but lowers the price target from $16 to $14.
August 29, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a 'Buy' rating on Health Catalyst but lowers the price target from $16 to $14.
The news is directly related to Health Catalyst (HCAT). While the 'Buy' rating is maintained, the lowering of the price target might indicate a potential short-term decrease in the stock price. However, the overall impact is neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100